Zevra Therapeutics Faces Investor Probe Following Regulatory Setback

The legal review, led by SueWallSt—a division of the litigation firm Levi & Korsinsky—focuses on whether Zevra provided misleading information regarding the regulatory prospects of arimoclomol, marketed as Meplyffa, for the treatment of Niemann-Pick disease type C. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) decision served as the catalyst for the sell-off, raising questions about the accuracy of prior corporate disclosures.

Investors who incurred losses during the July 24 market drop are now being evaluated for potential claims. Eligibility for the investigation depends on purchase dates and documented financial losses, rather than current share ownership. Attorneys state that participation involves no upfront costs, as the firm operates on a contingency basis. Those affected are encouraged to compile brokerage statements reflecting purchase prices and transaction dates to assist in the ongoing legal assessment.